A Single-Center Review of Resistant CMV Infection in Solid Organ Transplant Recipients (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.28; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "The development of resistance to standard therapies, valganciclovir (vGCV), the mainstay of CMV prophylaxis following SOT, and ganciclovir (GCV), the first line therapy for CMV infection, leads to limited treatment options with significant toxicities, higher mortality rates, and longer hospital stays...Once undergoing treatment for suspected resistance, treatment was escalated to either maribavir or foscarnet... Most patients developed CMV resistance while on prophylaxis with under-dosing of vGCV likely a key contributing factor. The challenge of dosing vGCV amid fluctuating renal function post-transplant highlights a key area for improvement, such as, closer renal function monitoring or the use of medications like letermovir that do not require renal adjustment. While ID involvement was infrequent early in CMV diagnosis and its impact on CMV treatment outcomes is unknown, we advocate for early ID consultation to enhance monitoring and clinical decision-making for..."
Clinical • Review • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
S. Tyler 1; A. Mills 2; D. Charles 3; C. Harris 4
|